8-K Announcements
6Material company update
May 18, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
May 7, 2026·SEC
Lipocine Inc.(LPCN)Earnings, Financials & Key Ratios
LPCN•NASDAQ
Price updated Jun 19, 2026
AboutLipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.Show more
- Revenue$2M-82.3%
- EBITDA-$10M-825.6%
- Net Income-$10M-115371.9%
- EPS (Diluted)-1.69-105525.0%
- Gross Margin-334.26%-434.3%
- EBITDA Margin-521.61%-5143.7%
- Operating Margin-524.69%-4986.9%
- Net Margin-487.05%-652988.7%
- ROE-54.28%-134450.7%
LPCN Key Insights
Lipocine Inc. (LPCN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.9x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 0/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 15 (bottom 15%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when LPCN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LPCN Price & Volume
Lipocine Inc. (LPCN) stock price & volume — 10-year historical chart
Loading chart...
LPCN Growth Metrics
Lipocine Inc. (LPCN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years58.12%
TTM-45.52%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-112.93%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-94.06%
Return on Capital
10 Years-55.09%
5 Years-29.51%
3 Years-42.61%
Last Year-58.47%
LPCN Recent Earnings
Lipocine Inc. (LPCN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 3/12 qtrs (38%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.54-5.9%
$0.51
Rev
$119,397-26.5%
$162,500
Q2 2026
Mar 9, 2026Metric
Actual
Est
EPS
$0.34+43.3%
$0.60
Rev
$1M+867.8%
$116,000
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.59-5.4%
$0.56
Rev
$114,574-51.9%
$238,000
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.41+0.0%
$0.41
Rev
$622,849+161.7%
$238,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.54vs $0.51-5.9% | $119,397vs $162,500-26.5% |
| Q2 2026 | Mar 9, 2026 | $0.34vs $0.60+43.3% | $1Mvs $116,000+867.8% |
| Q4 2025 | Nov 6, 2025 | $0.59vs $0.56-5.4% | $114,574vs $238,000-51.9% |
| Q3 2025 | Aug 5, 2025 | $0.41vs $0.41+0.0% | $622,849vs $238,000+161.7% |
Based on last 12 quarters of dataView full earnings history →
LPCN Peer Comparison
Lipocine Inc. (LPCN) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ANIP | 1.81B | 79.49 | 23.94 | 43.78% | 9.71% | 17.32% | 0.60 | |
 TLSA | 147.61M | 1.16 | -5.27 | -8.69% | 0.03 | |||
 NUVB | 1.93B | 5.56 | -9.27 | 6.99% | -102.06% | -44.1% | 0.03 | |
 CLDX | 2.16B | 32.43 | -8.32 | -78.63% | -345.96% | -50.72% | 0.00 | |
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% | ||
 AVDL | 2.1B | 21.64 | -42.43 | 5.05% | -0.11% | -0.33% | 0.02 | |
 MNKD | 1.22B | 3.94 | 197 | 22.23% | -6.63% | |||
 CLRB | 8.91M | 2.79 | -0.33 | -264.79% | 0.04 |
Compare LPCN vs Peers
Lipocine Inc. (LPCN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LPCN Income Statement
Lipocine Inc. (LPCN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 428.03K | 164.99K | 0 | 16.14M | 500K | -2.85M | 11.2M | 1.98M | 2M |
Revenue Growth % | - | - | -61.45% | -100% | - | -96.9% | -670.16% | 492.8% | -82.35% | -45.52% |
Cost of Goods Sold | 0 | 0 | 7.47M | 0 | 7.67M | 8.56M | 10.18M | 0 | 8.58M | 2.17M |
COGS % of Revenue | - | - | 4526.46% | - | 47.49% | 1711.38% | -356.92% | - | 434.26% | - |
Gross Profit | 0▲ 0% | 428.03K▲ 0% | -7.3M▼ 1806.2% | 0▲ 100.0% | 8.48M▲ 0% | -8.06M▼ 195.1% | -13.03M▼ 61.7% | 11.2M▲ 186.0% | -6.61M▼ 159.0% | -164.35K▲ 0% |
Gross Margin % | - | 100% | -4426.46% | - | 52.51% | -1611.38% | 456.92% | 100% | -334.26% | -8.21% |
Gross Profit Growth % | - | - | -1806.24% | 100% | - | -195.06% | -61.68% | 185.97% | -159% | - |
Operating Expenses | 20.98M | 12.09M | 5.6M | 18M | 5.33M | 4.06M | 4.9M | 12.35M | 3.76M | 11.97M |
OpEx % of Revenue | - | 2823.94% | 3392.37% | - | 33.02% | 812.5% | -172.05% | 110.31% | 190.43% | - |
Selling, General & Admin | 10.21M | 5.29M | 5.6M | 8.25M | 5.33M | 4.06M | 4.9M | 5M | 3.76M | 3.85M |
SG&A % of Revenue | - | 1235.69% | 3392.37% | - | 33.02% | 812.5% | -172.05% | 44.66% | 190.43% | - |
Research & Development | 11M | 6.46M | 7.47M | 9.75M | 0 | 0 | 0 | 7.35M | 0 | 10.27M |
R&D % of Revenue | - | 1510.34% | 4526.46% | - | - | - | - | 65.65% | - | - |
Other Operating Expenses | 0 | 0 | -7.47M | 0 | 0 | 0 | 0 | 0 | 0 | -1.03M |
Operating Income | -21.22M▲ 0% | -11.33M▲ 46.6% | -12.9M▼ 13.9% | -18M▼ 39.5% | 3.15M▲ 117.5% | -12.12M▼ 485.3% | -17.93M▼ 48.0% | -1.16M▲ 93.6% | -10.37M▼ 797.9% | -12.13M▲ 0% |
Operating Margin % | - | -2646.03% | -7818.83% | - | 19.49% | -2423.88% | 628.98% | -10.31% | -524.69% | -605.86% |
Operating Income Growth % | -14.95% | 46.62% | -13.9% | -39.5% | 117.48% | -485.29% | -47.95% | 93.56% | -797.93% | - |
EBITDA | -21.19M | -11.31M | -12.88M | -17.99M | 3.15M | -12.11M | -17.9M | -1.11M | -10.31M | -12.07M |
EBITDA Margin % | - | -2641.68% | -7809.47% | - | 19.49% | -2421.98% | 627.97% | -9.95% | -521.61% | -602.87% |
EBITDA Growth % | -15% | 46.64% | -13.95% | -39.64% | 117.48% | -484.95% | -47.83% | 93.78% | -825.61% | -88.03% |
D&A (Non-Cash Add-back) | 28.37K | 18.59K | 15.44K | 3.55K | 380 | 9.45K | 28.66K | 41.11K | 60.78K | 60.03K |
EBIT | -21.22M | -11.33M | -12.24M | -18M | -430.91K | -10.73M | -17.93M | -1.16M | -10.37M | -12.13M |
Net Interest Income | 0 | 0 | -343.25K | -310.97K | -135.59K | 545.48K | 1.37M | 1.15M | 744.07K | 696.13K |
Interest Income | 0 | 0 | - | 75.65K | 67.7K | 572.58K | 1.37M | 1.15M | 744.07K | 696.13K |
Interest Expense | 0 | 0 | 343.25K | 386.62K | 203.29K | 27.1K | 0 | 0 | 0 | 0 |
Other Income/Expense | 235.82K | -333.5K | -106.85K | -2.97M | -3.78M | 1.36M | 1.58M | 1.16M | 744.07K | 696.13K |
Pretax Income | -20.98M▲ 0% | -11.66M▲ 44.4% | -13.01M▼ 11.6% | -20.96M▼ 61.2% | -634.2K▲ 97.0% | -10.76M▼ 1596.3% | -16.35M▼ 52.0% | 9.03K▲ 100.1% | -9.63M▼ 106679.3% | -11.43M▲ 0% |
Pretax Margin % | - | -2723.94% | -7883.6% | - | -3.93% | -2151.59% | 573.57% | 0.08% | -487.04% | -571.1% |
Income Tax | 700 | 700 | 200 | 200 | 200 | 681 | 755 | 681 | 200 | 0 |
Effective Tax Rate % | -0% | -0.01% | -0% | -0% | -0.03% | -0.01% | -0% | 7.54% | -0% | 0% |
Net Income | -20.98M▲ 0% | -11.66M▲ 44.4% | -13.01M▼ 11.6% | -20.96M▼ 61.2% | -634.4K▲ 97.0% | -10.76M▼ 1595.9% | -16.35M▼ 52.0% | 8.35K▲ 100.1% | -9.63M▼ 115371.9% | -11.43M▲ 0% |
Net Margin % | - | -2724.11% | -7883.72% | - | -3.93% | -2151.73% | 573.59% | 0.07% | -487.05% | -571.1% |
Net Income Growth % | -10.6% | 44.43% | -11.56% | -61.18% | 96.97% | -1595.88% | -51.99% | 100.05% | -115371.85% | -112.93% |
Net Income (Continuing) | -20.98M | -11.66M | -13.01M | -20.96M | -634.4K | -10.76M | -16.35M | 8.35K | -9.63M | -11.43M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -17.85▲ 0% | -9.28▲ 48.0% | -8.54▲ 8.0% | -6.40▲ 25.1% | -0.12▲ 98.1% | -2.05▼ 1608.3% | -3.14▼ 53.2% | -0.00▲ 99.9% | -1.69▼ 105525.0% | -1.68▲ 0% |
EPS Growth % | -0.96% | 48.01% | 7.97% | 25.06% | 98.13% | -1608.33% | -53.17% | 99.95% | - | -94.06% |
EPS (Basic) | -17.79 | -9.35 | -8.54 | -6.46 | -0.19 | -2.15 | -3.14 | 0.00 | -1.77 | - |
Diluted Shares Outstanding | 1.18M | 1.26M | 1.52M | 3.28M | 5.15M | 5.26M | 5.27M | 5.42M | 5.71M | 6.79M |
Basic Shares Outstanding | 1.18M | 1.25M | 1.52M | 3.25M | 3.3M | 4.99M | 5.27M | 5.34M | 5.45M | 6.79M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
LPCN Balance Sheet
Lipocine Inc. (LPCN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 25.22M | 20.81M | 19.63M | 25.33M | 46.38M | 34.14M | 22.86M | 22.32M | 16.88M | 25.24M |
Cash & Short-Term Investments | 21.47M | 15.25M | 14.07M | 19.67M | 44.62M | 32.53M | 22.04M | 21.63M | 14.93M | 24.73M |
Cash Only | 3.21M | 8.08M | 9.73M | 19.22M | 2.95M | 3.15M | 4.77M | 6.21M | 5.21M | 5.02M |
Short-Term Investments | 18.26M | 7.17M | 4.34M | 449.99K | 41.67M | 29.38M | 17.26M | 15.43M | 9.72M | 19.71M |
Accounts Receivable | 3.34M | 38.51K | 16.52K | 391 | 247.25K | 659.86K | 52.25K | 120.45K | 14.19K | 0 |
Days Sales Outstanding | - | 32.84 | 36.55 | - | 5.59 | 481.69 | -6.69 | 3.93 | 2.62 | 11.45 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 5M | 5M | 5M | 0 | 945.32K | 773.42K | 567.91K | 1.93M | 515.86K |
Total Non-Current Assets | 105.82K | 42.75K | 27.31K | 23.75K | 6.1M | 3.41M | 139.85K | 188.83K | 128.05K | 113.23K |
Property, Plant & Equipment | 75.07K | 19K | 3.55K | 0 | 7.21K | 131.59K | 116.09K | 165.07K | 104.29K | 89.48K |
Fixed Asset Turnover | - | 22.53x | 46.42x | - | 2238.36x | 3.80x | -24.56x | 67.84x | 18.95x | 17.94x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 2.02M | 3.25M | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 30.75K | 23.75K | 23.75K | 23.75K | 4.07M | 23.75K | 23.75K | 23.75K | 23.75K | 23.75K |
Total Assets | 25.33M▲ 0% | 20.85M▼ 17.7% | 19.66M▼ 5.7% | 25.35M▲ 29.0% | 52.48M▲ 107.0% | 37.54M▼ 28.5% | 23M▼ 38.7% | 22.51M▼ 2.1% | 17.01M▼ 24.5% | 25.36M▲ 0% |
Asset Turnover | - | 0.02x | 0.01x | - | 0.31x | 0.01x | -0.12x | 0.50x | 0.12x | 0.10x |
Asset Growth % | -7.38% | -17.66% | -5.72% | 28.97% | 107.01% | -28.47% | -38.73% | -2.13% | -24.45% | -42.44% |
Total Current Liabilities | 6.35M | 4.49M | 4.96M | 6.58M | 5.62M | 1.68M | 2.63M | 1.51M | 2.53M | 2.53M |
Accounts Payable | 598.07K | 671.28K | 1.18M | 1.6M | 1.29M | 600.39K | 1.4M | 271.7K | 971.82K | 1.56M |
Days Payables Outstanding | - | - | 57.78 | - | 61.39 | 25.61 | 50.08 | - | 41.32 | 161.69 |
Short-Term Debt | 0 | 3.33M | 3.33M | 3.33M | 2.31M | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 320K | 320K | 1.28M |
Other Current Liabilities | 4.25M | 0 | 0 | 0 | 1M | 0 | 17.17K | 0 | 1.24M | 645.12K |
Current Ratio | 3.97x | 4.63x | 3.95x | 3.85x | 8.26x | 20.34x | 8.69x | 14.75x | 6.68x | 9.99x |
Quick Ratio | 3.97x | 4.63x | 3.95x | 3.85x | 8.26x | 20.34x | 8.69x | 14.75x | 6.68x | 9.99x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -150.24 |
Total Non-Current Liabilities | 0 | 6.93M | 8.41M | 3.43M | 1.3M | 229.86K | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 6.93M | 3.81M | 2.26M | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 4.59M | 1.17M | 1.3M | 229.86K | 0 | 0 | 0 | 0 |
Total Liabilities | 6.35M | 11.42M | 13.37M | 10.01M | 6.91M | 1.91M | 2.63M | 1.51M | 2.53M | 2.53M |
Total Debt | 0 | 10.26M | 7.15M | 5.59M | 2.31M | 0 | 0 | 0 | 0 | 0 |
Net Debt | -3.21M | 2.18M | -2.58M | -13.63M | -639.73K | -3.15M | -4.77M | -6.21M | -5.21M | -5.02M |
Debt / Equity | - | 1.09x | 1.14x | 0.36x | 0.05x | - | - | - | - | 0.00x |
Debt / EBITDA | - | - | - | - | 0.73x | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | -0.20x | - | - | - | - | 0.42x |
Interest Coverage | - | - | -35.66x | -46.55x | -2.12x | -396.00x | - | - | - | - |
Total Equity | 18.98M▲ 0% | 9.43M▼ 50.3% | 6.29M▼ 33.3% | 15.34M▲ 144.0% | 45.57M▲ 197.0% | 35.63M▼ 21.8% | 20.37M▼ 42.8% | 21M▲ 3.1% | 14.48M▼ 31.1% | 22.83M▲ 0% |
Equity Growth % | -27.05% | -50.3% | -33.35% | 144% | 197.03% | -21.8% | -42.84% | 3.08% | -31.05% | -57.41% |
Book Value per Share | 16.09 | 7.51 | 4.13 | 4.68 | 8.84 | 6.78 | 3.87 | 3.87 | 2.54 | 3.36 |
Total Shareholders' Equity | 18.98M | 9.43M | 6.29M | 15.34M | 45.57M | 35.63M | 20.37M | 21M | 14.48M | 22.83M |
Common Stock | 2.13K | 2.17K | 3.77K | 7K | 8.83K | 8.85K | 8.86K | 8.86K | 8.94K | 9.08K |
Retained Earnings | -126.4M | -138.06M | -151.07M | -172.03M | -172.67M | -183.43M | -199.78M | -199.77M | -209.4M | -213.07M |
Treasury Stock | -40.71K | -40.71K | -40.71K | -40.71K | -40.71K | -40.71K | -40.71K | -40.71K | -40.71K | 0 |
Accumulated OCI | -4.62K | -963 | -38 | 0 | -18.02K | -20.32K | 7.26K | 9.14K | 4.45K | -7.19K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LPCN Cash Flow Statement
Lipocine Inc. (LPCN) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -16.7M | -12.08M | -11.67M | -15.3M | -4.41M | -11.97M | -11.87M | -1.22M | -9.76M | -10.05M |
Operating CF Margin % | - | -2821.95% | -7070.86% | - | -27.33% | -2393.76% | 416.23% | -10.91% | -493.79% | - |
Operating CF Growth % | 8.64% | 27.68% | 3.42% | -31.17% | 71.17% | -171.32% | 0.86% | 89.71% | -699.25% | -267.07% |
Net Income | -20.98M | -11.66M | -13.01M | -20.96M | -634.4K | -10.76M | -16.35M | 8.35K | -9.63M | -11.43M |
Depreciation & Amortization | 28.37K | 18.59K | 15.44K | 3.55K | 380 | 9.45K | 28.66K | 41.11K | 60.78K | 60.03K |
Stock-Based Compensation | 2.72M | 1.46M | 1.04M | 1.37M | 603.95K | 636.14K | 654.44K | 408.55K | 242.5K | 171.49K |
Deferred Taxes | 0 | -160.87K | 0 | 0 | 159.69K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -99.89K | 259.87K | -179.5K | 2.76M | 53.75K | -932.15K | 1.8M | -715.03K | -192.94K | -165.75K |
Working Capital Changes | 1.64M | -1.99M | 469.35K | 1.52M | -4.59M | -923.63K | 2.01M | -964.21K | -243.56K | 1.32M |
Change in Receivables | -3.3M | 3.3M | 21.99K | 16.13K | -246.86K | 384.9K | 738.11K | -68.19K | 106.26K | 1.09M |
Change in Inventory | 0 | 0 | 0 | 0 | 246.86K | -384.9K | 0 | 0 | 0 | 0 |
Change in Payables | 352.15K | 73.21K | 510.96K | 414.98K | -307.88K | -688.95K | 795.59K | -1.12M | 700.13K | 1.2M |
Cash from Investing | 3.13M | 11.29M | 3M | 3.89M | -43.78M | 14.29M | 13.08M | 2.45M | 5.89M | -3.13M |
Capital Expenditures | 0 | 0 | 0 | 0 | -7.59K | -133.83K | -13.17K | -90.09K | 0 | 0 |
CapEx % of Revenue | - | - | - | - | 0.05% | 26.77% | -0.46% | 0.8% | - | 0% |
Acquisitions | 0 | 0 | 0 | 0 | 43.78B | -14.29M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 3.13M | 7K | 0 | 0 | -43.78B | 14.29M | 0 | 0 | 0 | 0 |
Cash from Financing | 11.23M | 10.65M | 10.32M | 20.9M | 26.92M | -2.13M | 404.57K | 209.34K | 2.87M | 14.84M |
Debt Issued (Net) | 0 | 10M | -3.33M | -1.43M | -3.33M | -2.32M | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 10.64M | 652.33K | 13.6M | 14.66M | 30.25M | 211.42K | 404.57K | 209.34K | 2.87M | 14.84M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | -21.7K | 0 | 0 | 0 | 0 |
Other Financing | 581.14K | 0 | 56.35K | 7.67M | 11.69K | -21.7K | 0 | 0 | 0 | 0 |
Net Change in Cash | -2.35M▲ 0% | 9.87M▲ 519.9% | 1.65M▼ 83.3% | 9.49M▲ 474.7% | -21.27M▼ 324.1% | 197.94K▲ 100.9% | 1.62M▲ 720.1% | 1.43M▼ 11.6% | -1M▼ 169.7% | 1.66M▲ 0% |
Free Cash Flow | -16.7M▲ 0% | -12.08M▲ 27.7% | -11.67M▲ 3.4% | -15.3M▼ 31.2% | -4.42M▲ 71.1% | -12.1M▼ 173.9% | -11.88M▲ 1.8% | -1.31M▲ 89.0% | -9.76M▼ 644.3% | -10.05M▲ 0% |
FCF Margin % | - | -2821.95% | -7070.86% | - | -27.38% | -2420.53% | 416.69% | -11.71% | -493.79% | -501.88% |
FCF Growth % | 8.94% | 27.68% | 3.42% | -31.17% | 71.12% | -173.88% | 1.85% | 88.96% | -644.34% | -76.66% |
FCF per Share | -14.16 | -9.62 | -7.66 | -4.67 | -0.86 | -2.30 | -2.25 | -0.24 | -1.71 | -1.48 |
FCF Conversion (FCF/Net Income) | 0.80x | 1.04x | 0.90x | 0.73x | 6.95x | 1.11x | 0.73x | -146.22x | 1.01x | 0.88x |
Interest Paid | 0 | 533.54K | 545.54K | 276.02K | 149.54K | 21.26K | 0 | 0 | 0 | 0 |
Taxes Paid | 700 | 700 | 200 | 200 | 200 | 200 | 225 | 681 | 0 | 0 |
LPCN Key Ratios
Lipocine Inc. (LPCN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -93.26% | -82.07% | -165.47% | -193.85% | -2.08% | -26.5% | -58.4% | 0.04% | -54.28% | -66.69% |
Return on Invested Capital (ROIC) | -87.86% | -62.04% | -126.28% | -497.87% | 10.12% | -23.48% | -55.94% | -5.7% | -64.65% | -75.17% |
Gross Margin | - | 100% | -4426.46% | - | 52.51% | -1611.38% | 456.92% | 100% | -334.26% | -8.21% |
Net Margin | - | -2724.11% | -7883.72% | - | -3.93% | -2151.73% | 573.59% | 0.07% | -487.05% | -571.1% |
Debt / Equity | - | 1.09x | 1.14x | 0.36x | 0.05x | - | - | - | - | 0.00x |
Interest Coverage | - | - | -35.66x | -46.55x | -2.12x | -396.00x | - | - | - | - |
FCF Conversion | 0.80x | 1.04x | 0.90x | 0.73x | 6.95x | 1.11x | 0.73x | -146.22x | 1.01x | 0.88x |
Revenue Growth | - | - | -61.45% | -100% | - | -96.9% | -670.16% | 492.8% | -82.35% | -45.52% |
Related:LPCN Dividend History·LPCN Revenue History·LPCN Price History·LPCN P/E History·LPCN Financial Ratios·LPCN Institutional Holders
LPCN SEC Filings & Documents
Lipocine Inc. (LPCN) SEC filings — annual & quarterly reports (10-K, 10-Q)
LPCN Frequently Asked Questions
Lipocine Inc. (LPCN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Lipocine Inc. (LPCN) reported $2.0M in revenue for fiscal year 2025.
Lipocine Inc. (LPCN) saw revenue decline by 82.3% over the past year.
Lipocine Inc. (LPCN) reported a net loss of $11.4M for fiscal year 2025.
Dividend & Returns
Lipocine Inc. (LPCN) has a return on equity (ROE) of -54.3%. Negative ROE indicates the company is unprofitable.
Lipocine Inc. (LPCN) had negative free cash flow of $10.0M in fiscal year 2025, likely due to heavy capital investments.